Table 2.
Day |
Days After Starting Avelumab Treatment |
Normal Range | |||||||
---|---|---|---|---|---|---|---|---|---|
126 | 132 | 148 | 168 | 170 | 182 | 196 | 224 | ||
U Osm (mOsm/Kg) | 241 | 380 | 382 | 467 | 493 | 505 | 557 | 596 | 300–900 |
S Osm (mOsm/Kg) | 303 | 303 | 296 | 298 | 299 | 300 | 299 | 298 | 278–298 |
S Sodium (mmol/L) | 147 | 144 | 142 | 143 | 142 | 144 | 142 | 141 | 136–145 |
Sp Gravity | 1.00 | 1.01 | 1.01 | 1.011 | 1.016 | 1.002–1.035 |
The patient presented with DI symptoms on day 126 after starting avelumab and received DDAVP from day 132 to day 167 (shaded days).
Abbreviations: S Osm, serum osmolality; Sp Gravity, urine specific gravity; S Sodium, serum sodium; U Osm, urine osmolality.